What it is, whether it works, and how people actually combine it. Browse by what you want, by the stacks people search, or molecule by molecule.
A non-peptide small-molecule NNMT inhibitor marketed for fat-cell metabolism, research-stage only.
A topical cosmetic peptide marketed as a 'Botox-like' expression-line softener, low-risk, well-established in skincare.
A pro-apoptotic peptide that targets the blood supply of fat tissue, striking animal fat loss, but documented kidney toxicity.
A fragment of growth hormone marketed for fat loss, with weak human evidence.
A non-erythropoietic peptide derived from EPO, studied for neuropathic pain and inflammation, some human trial data.
A recovery peptide people take in hope of speeding the healing of tendon, joint, muscle, and gut lining.
A long-acting amylin analog studied as the satiety layer that amplifies a GLP-1, the canonical 'companion' molecule.
A porcine-derived neurotrophic peptide preparation with a long clinical heritage in stroke and dementia abroad, the most-evidenced nootropic peptide.
A growth-hormone-releasing peptide usually stacked with Ipamorelin, but non-compoundable in the US.
An angiotensin-IV-derived peptide reported as an extremely potent driver of new synapse formation, essentially no human data.
Delta-sleep-inducing peptide, studied for sleep quality and stress.
An oral medicine, not a peptide, that raises the body's own testosterone, a fertility-sparing alternative to TRT.
A short peptide studied for sleep and circadian support.
A myostatin-inhibiting protein that can drive extreme muscle growth, high-risk, WADA-banned, research-only.
A senolytic peptide designed to clear senescent ('zombie') cells by triggering their apoptosis, preclinical only.
A copper peptide used topically in skin and hair cosmetics.
A second-generation GH-releasing peptide, more selective than GHRP-6 but still restricted and research-only.
A first-generation GH-releasing peptide that strongly stimulates appetite as well as GH, restricted and research-only.
A synthetic GnRH used as a TRT adjunct to preserve fertility and natural testicular function, historically approved, now compounded.
A potent ghrelin-receptor GH-releasing peptide from the legacy bodybuilding toolkit, restricted, with prolactin and desensitization issues.
A mitochondrial-DNA-encoded cytoprotective peptide studied in aging and metabolic stress, research-stage.
A long-acting IGF-1 analog used in bodybuilding circles for muscle and recovery, potent, banned in sport, and research-only.
A selective growth-hormone secretagogue, the usual partner to CJC-1295, also non-compoundable in the US.
A reproductive-hormone signaling peptide studied for libido and fertility pathways.
A small peptide people ask about for gut and inflammatory support.
A natural cathelicidin antimicrobial and immune-signaling peptide, restricted, and pro-inflammatory in the wrong context.
An off-label low dose of an approved drug, not a peptide, used for immune and inflammatory conditions.
A first-line diabetes drug, not a peptide, widely studied as a longevity and metabolic agent.
An orally-active growth-hormone secretagogue, not a peptide, studied for GH/IGF-1 and appetite.
A mitochondrial-derived peptide studied for metabolism and energy.
A coenzyme involved in how your cells make and use energy.
An investigational non-peptide, small-molecule oral GLP-1 agonist, 'GLP-1 in a daily pill.'
The bonding-and-arousal neuropeptide, FDA-approved as Pitocin for labor, with off-label intranasal use for intimacy and connection.
A spadin-derived peptide that blocks the TREK-1 channel, studied preclinically for fast-acting antidepressant effects.
A mechano-growth-factor splice variant of IGF-1 used for local muscle repair, research-only, restricted.
A short 'bioregulator' peptide from the Russian Khavinson school, claimed for brain and longevity support, thin Western validation.
An FDA-approved peptide (as Vyleesi) that raises sexual desire by acting on the brain's arousal pathways, not blood flow.
An mTOR-inhibiting drug, not a peptide, with the deepest lifespan-extension evidence in animal models.
An investigational triple GLP-1/GIP/glucagon agonist posting the largest weight-loss numbers recorded so far.
A nootropic peptide studied for calm and anxiety support.
A GLP-1 medicine that lowers appetite and blood sugar, the most-studied molecule in the whole category.
A nootropic peptide studied for focus and mental clarity.
A peptide that nudges your body's own growth-hormone axis.
A mitochondria-targeting peptide that binds cardiolipin to restore ATP production, and, as of Sept 2025, an FDA-approved drug for one rare disease.
An investigational GLP-1/glucagon dual agonist studied for both weight and liver disease (MASH).
A synthetic fragment usually discussed alongside BPC-157 for soft-tissue recovery.
A growth-hormone-axis peptide with FDA-approved origins.
A non-peptide triple-reuptake inhibitor studied as an appetite suppressant, not US-approved, with cardiovascular and psychiatric cautions.
A thymic peptide preparation from the Khavinson school, claimed for immune restoration, limited independent validation.
An immune-modulating peptide with the strongest evidence of the education-only set, but not on the PCAC agenda.
A dual GIP/GLP-1 medicine with the strongest weight and metabolic trial data in the category.
A long-acting GnRH agonist FDA-approved for oncology/endocrine use (Trelstar); biohacker 'hormone restart' use is off-label and illicit.
A Khavinson-school dipeptide 'bioregulator' claimed for immune and longevity support, minimal independent evidence.
An investigational dual GLP-1/GIP agonist (Viking) being developed in both injectable and oral forms.
The best vetted resources on the open web, studies, lectures, credentialed voices. We link, we don't endorse.
Browse the canon How we gradeWhy a molecule gets an A or a D, why the evidence grade and the availability verdict are two separate signals, and what would change a grade.
Read the methodology FDA categoriesThe three tiers that decide whether a pharmacy can compound a peptide, and why "Category 1" is not the same as FDA-approved.
Read the explainer The July PCAC meetingThe seven peptides under review, what happens after a favorable vote, and why the meeting is a starting line, not a finish line.
Read the explainerAnswer a few questions and a licensed clinician maps a plan to your goals, only what's legitimately available, nothing you can't actually get.
Reviewed by the Peptós.LIFE clinical team · Last reviewed June 16, 2026. Statuses read live from the FDA Tracker dataset. Compounded medications are prepared for an individual patient and are not FDA-approved. PCAC is advisory, a favorable vote leads to rulemaking, not instant availability.